<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131041">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01798277</url>
  </required_header>
  <id_info>
    <org_study_id>NERG-02</org_study_id>
    <nct_id>NCT01798277</nct_id>
  </id_info>
  <brief_title>Trial Comparing Ablation With Medical Therapy in Patients With Ventricular Tachycardia</brief_title>
  <acronym>VeTAMed</acronym>
  <official_title>Ablation Versus Medical Therapy in Patients With Coronary Artery Disease and Sustained Ventricular Tachycardia Randomized Trial (VeTAMed)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Newmarket Electrophysiology Research Group Inc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Newmarket Electrophysiology Research Group Inc</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare antiarrhythmic drug therapy with catheter ablation using the
      SmartTOUCH catheter (Biosense Webster Inc.) as treatment for patients with ventricular
      tachycardia and coronary artery disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized prospective cohort study to compare the impact of catheter
      ablation with antiarrhythmic drug therapy for treating patients with sustained ventricular
      tachycardia (VT) and coronary artery disease. Patients that meet all inclusion criteria and
      no exclusion criteria will be recruited to the study cohort. After baseline measurements are
      taken, patients will be randomized in a 2:1 fashion to either undergo radiofrequency
      catheter ablation or receive antiarrhythmic drug therapy (amiodarone or sotalol). The
      in-clinic appointments include: enrollment, baseline, intervention, and follow-up every
      three months for one year post-ablation. At each follow-up visit, electrogram (ECG) and
      Holter monitoring tests will be performed to measure any episodes of ventricular
      tachyarrhythmia. Furthermore, interrogation of the patient's implantable cardioverter
      defibrillator (ICD) will be performed at all follow-up visits to detect any episodes of
      ventricular tachyarrhythmia that required antitachycardia pacing (ATP) or shocks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Recurrence of Ventricular Tachycardia</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of any appropriate ATPs/shocks and/or presentations of sustained (&gt;30sec) VT on Holter or ECG recording at 3, 6, 9 and 12 months after intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to First Shock/ATP for VT or to First Presentation of Sustained VT</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in time to first ATP/shock or presentation of sustained (&gt;30sec) VT on Holter or ECG recording at 3, 6, 9 and 12 months after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total mortality</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in mortality status at 3, 6, 9 and 12 months after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sudden cardiac death</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in sudden cardiac death status at 3, 6, 9 and 12 months after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Syncope</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in syncope status at 3, 6, 9 and 12 months after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalizations</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in number of hospitalizations at 3, 6, 9 and 12 months after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL measures</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in QOL measures at 6 and 12 months after intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Catheter Ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiofrequency ablation procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Antiarrhythmic drug therapy will include amiodarone or sotalol. Which antiarrhythmic drug will prescribed per patient depends on the observing physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Catheter Ablation</intervention_name>
    <description>Catheter ablation of ventricular tachycardia will employ three-dimensional mapping Fast Anatomical Mapping or CARTOSOUND technology (Biosense Webster Inc.), and the Thermocool Navistar catheter (Biosense Webster Inc.).</description>
    <arm_group_label>Catheter Ablation</arm_group_label>
    <other_name>Ablation of:</other_name>
    <other_name>- Ischemic ventricular tachycardia</other_name>
    <other_name>- Sustained monomorphic ventricular tachycardia</other_name>
    <other_name>- Clinical ventricular tachycardia</other_name>
    <other_name>- Hemodynamically stable/unstable ventricular tachycardia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medical therapy (sotalol or amiodarone)</intervention_name>
    <description>Patients will be tiered to one of two possible antiarrhythmic drugs (sotalol or amiodarone).</description>
    <arm_group_label>Medical therapy</arm_group_label>
    <other_name>Sotalol - Betapace, Betapace AF, Sotalex, Sotacor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sustained monomorphic VT (&gt;30 seconds, or requiring appropriate ICD therapy in
             patients with ICDs)

          -  Documented ischemic heart disease with no further options for revascularization

          -  Ability and willingness to give written informed consent to participate in the trial

        Exclusion Criteria:

          -  VT in the setting of metabolic abnormalities or acute ischemia if coronary lesions
             suitable for revascularization are identified.

          -  Acute ischemia with eligibility for revascularization

          -  Significant peripheral arterial disease preventing transvascular access to the left
             ventricle.

          -  Patients with arrhythmogenic right ventricular cardiomyopathy (ARVC), hypertrophic
             cardiomyopathy, Brugada syndrome, Long QT syndromes, dilated cardiomyopathy

          -  Prior long term therapy with a Class III or Class IC antiarrhythmic agent (longer
             than 2 weeks)

          -  Patient is or may be potentially pregnant

          -  Patient has a mechanical heart valve

          -  Myocardial infarction within the past 90 days

          -  Stroke within the past 90 days

          -  New York Heart Association (NYHA) functional class IV

          -  Hemorrhagic manifestations, bleeding diathesis, or impairment of hemostasis

          -  Lesions at risk of clinically significant bleeding (e.g., extensive cerebral
             infarction within the last 6 months, active peptic ulcer disease with recent
             bleeding)

          -  Prior VT ablation procedure

          -  Contraindication or allergy to contrast media, routine procedural medications or
             catheter materials

          -  Contraindications to an interventional procedure

          -  Life expectancy is less than 6 months

          -  Incessant or multiple episodes of VT requiring immediate therapy with medications or
             ablation

          -  Untreated hypothyroidism or hyperthyroidism (euthyroid or thyroid hrt is acceptable)

          -  Current enrolment in another investigational drug or device study

          -  There are other conditions present that the investigator feels would be problematic
             or would restrict or limit the participation for the patient for the entire study
             period

          -  Absolute contraindication to the use of heparin or warfarin

          -  Documented intra-arterial thrombus, ventricular thrombus, (less than 6 months after
             detection of thrombus), tumor or other abnormality that precludes catheter
             introduction
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yaariv Khaykin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Newmarket Electrophysiology Research Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lauren Chun, MSc</last_name>
    <phone>905-895-4521</phone>
    <phone_ext>5012</phone_ext>
    <email>lchun@southlakeregional.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southlake Regional Health Centre</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Chun, MSc</last_name>
      <phone>905-895-4521</phone>
      <phone_ext>5012</phone_ext>
      <email>lchun@southlakeregional.org</email>
    </contact>
    <contact_backup>
      <last_name>Sherri Patterson, RN</last_name>
      <phone>905-895-4521</phone>
      <phone_ext>2149</phone_ext>
      <email>spatterson@southlakeregional.org</email>
    </contact_backup>
    <investigator>
      <last_name>Yaariv Khaykin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 21, 2013</lastchanged_date>
  <firstreceived_date>February 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Keywords provided by Newmarket Electrophysiology Research Group Inc:</keyword>
  <keyword>Ventricular tachycardia</keyword>
  <keyword>Ventricular tachyarrhythmia</keyword>
  <keyword>Ablation</keyword>
  <keyword>Coronary artery disease</keyword>
  <keyword>Ischemic heart disease</keyword>
  <keyword>Amiodarone</keyword>
  <keyword>Sotalol</keyword>
  <keyword>Anti-Arrhythmia Agents</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Additional relevant MeSH terms:</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Arrhythmias, Cardiac</keyword>
  <keyword>Heart Diseases</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Pathologic Processes</keyword>
  <keyword>Catheter Ablation, Radiofrequency</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amiodarone</mesh_term>
    <mesh_term>Anti-Arrhythmia Agents</mesh_term>
    <mesh_term>Sotalol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
